This is a multi-center, randomized controlled, prospective clinical study.
Willingness to provide written informed consent;
Age ≥18 and ≤75 years;
Treatment-naïve for malignant disease;
Resectable stage III-IVA hypopharyngeal carcinoma with response of PR ≥ 50% after neoadjuvant therapy according to RECIST 1.1 ;
Pregnancy or breastfeeding status;
Hypersensitivity to sintilimab, nab-paclitaxel, or their formulation components;
Poorly controlled cardiovascular conditions or other diseases;
Active or documented history of autoimmune diseases requiring systemic treatment;
Eye & ENT Hospital of Fudan University
Lead sponsor